ICON Public FY2025 EPS Estimate Decreased by Leerink Partnrs

ICON Public Limited (NASDAQ:ICLR) – Analysts at Leerink Partnrs cut their FY2025 earnings estimates for shares of ICON Public in a research report issued on Tuesday, January 14th. Leerink Partnrs analyst M. Cherny now expects that the medical research company will post earnings of $13.44 per share for the year, down from their prior forecast of $13.98. The consensus estimate for ICON Public’s current full-year earnings is $13.41 per share. Leerink Partnrs also issued estimates for ICON Public’s FY2026 earnings at $15.67 EPS and FY2027 earnings at $17.73 EPS.

ICON Public (NASDAQ:ICLR) last posted its quarterly earnings data on Wednesday, October 23rd. The medical research company reported $3.35 earnings per share for the quarter, missing the consensus estimate of $3.72 by ($0.37). ICON Public had a return on equity of 11.91% and a net margin of 9.00%. The business had revenue of $2.03 billion during the quarter, compared to the consensus estimate of $2.13 billion. During the same period last year, the business posted $3.10 earnings per share. The business’s revenue was down 1.2% on a year-over-year basis.

Several other research firms also recently weighed in on ICLR. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $263.00 price target on shares of ICON Public in a research note on Wednesday. JPMorgan Chase & Co. decreased their target price on ICON Public from $375.00 to $280.00 and set an “overweight” rating for the company in a research report on Friday, October 25th. Truist Financial reaffirmed a “buy” rating and issued a $284.00 price target (down previously from $295.00) on shares of ICON Public in a research report on Wednesday, December 18th. Leerink Partners reiterated an “outperform” rating and issued a $255.00 target price (down previously from $270.00) on shares of ICON Public in a report on Tuesday, November 19th. Finally, Citigroup reduced their target price on ICON Public from $300.00 to $290.00 and set a “buy” rating for the company in a report on Monday, January 6th. Four investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $287.00.

ICON Public Stock Performance

NASDAQ:ICLR opened at $198.11 on Friday. The company has a quick ratio of 1.34, a current ratio of 1.34 and a debt-to-equity ratio of 0.35. ICON Public has a twelve month low of $183.38 and a twelve month high of $347.72. The company has a fifty day moving average of $209.71 and a 200-day moving average of $268.23. The firm has a market capitalization of $16.34 billion, a P/E ratio of 22.09, a P/E/G ratio of 1.59 and a beta of 1.20.

Institutional Trading of ICON Public

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Foyston Gordon & Payne Inc bought a new stake in ICON Public during the 3rd quarter worth approximately $11,672,000. Icon Wealth Advisors LLC grew its position in shares of ICON Public by 861.1% during the 3rd quarter. Icon Wealth Advisors LLC now owns 13,215 shares of the medical research company’s stock valued at $3,797,000 after purchasing an additional 11,840 shares in the last quarter. Sara Bay Financial bought a new position in shares of ICON Public in the third quarter worth $1,143,000. Whittier Trust Co. raised its position in shares of ICON Public by 12.3% in the third quarter. Whittier Trust Co. now owns 4,020 shares of the medical research company’s stock worth $1,155,000 after buying an additional 441 shares in the last quarter. Finally, Avior Wealth Management LLC boosted its stake in ICON Public by 76.0% during the fourth quarter. Avior Wealth Management LLC now owns 894 shares of the medical research company’s stock valued at $187,000 after buying an additional 386 shares during the period. 95.61% of the stock is currently owned by institutional investors.

ICON Public Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.